Corlanor

Chemical Nameivabradine
Dosage FormTablet (oral; 5 mg, 7.5 mg); solution (oral; 5 mg/5 mL)
Drug ClassChannel blockers
SystemCardiovascular
CompanyAmgen Inc.
Approval Year2015

Indication

  • To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
  • For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Corlanor (ivabradine) Prescribing Information 2019Amgen Inc., Thousand Oaks, CA